Premium
Efficacy and Safety of Ecabet Sodium as an Adjuvant Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta‐Analysis
Author(s) -
Wang Youhua,
Wang Ben,
Lv Zhi Fa,
Yang Yang,
Wang Fucai,
Wang Hui,
Chen Shuping,
Xie Yong,
Zhou Xiaojiang
Publication year - 2014
Publication title -
helicobacter
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.206
H-Index - 79
eISSN - 1523-5378
pISSN - 1083-4389
DOI - 10.1111/hel.12136
Subject(s) - medicine , cochrane library , randomized controlled trial , helicobacter pylori , clarithromycin , meta analysis , gastroenterology , adjuvant therapy , amoxicillin , antibiotics , cancer , microbiology and biotechnology , biology
Background Several studies have reported that the application of ecabet sodium during the eradication of Helicobacter pylori can improve the eradication rate and reduce therapy‐associated side effects. However, the efficacy and safety of this therapy are controversial. Objectives To determine whether ecabet sodium improves the eradication rate of H . pylori and examine treatment safety by conducting a meta‐analysis based on randomized controlled trials ( RCT s). Methods Literature searches were conducted in the following databases: PubMed, Embase, the Cochrane Library, the Science Citation Index, the China National Knowledge Infrastructure Database, and the Wanfang Database. A meta‐analysis of all RCT s comparing ecabet sodium supplementation with nonecabet sodium‐containing therapy was performed. Results Thirteen RCT s that included a total of 1808 patients were assessed. The meta‐analysis showed that the eradication rate in the ecabet sodium‐containing quadruple therapy group was higher than that in the standard triple therapy group (84.5% vs 74.55%, OR 1.757 (95% CI : 1.307 to 2.362), p < .001). The analysis also showed that the eradication rate in the ecabet sodium‐containing triple therapy group was significantly higher than that in the PPI plus amoxicillin or clarithromycin therapy group (74.6% vs 43.9%, OR 3.727 (95% CI : 2.320 to 5.988), p < .001)( ITT ), (74.6% vs 43.9%, OR 3.863 (95% CI : 2.369 to 6.298), p < .001) ( PP ). Furthermore, our meta‐analysis suggested that the occurrence of side effects did not significantly differ between patients receiving ecabet sodium‐containing therapy and patients receiving nonecabet sodium‐containing therapy (14.0% vs 13.3%, OR 1.055 (95% CI : 0.632 to 1.759), p = .839). Conclusion Supplementation with ecabet sodium during H. pylori eradication therapy improves the eradication rate. The use of ecabet sodium does not increase the side effects based on our meta‐analysis.